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Abstract
Background: The increasing use of highly active antiretroviral therapy (HAART) and pneumococcal immunization
along with shifting community exposures may have altered the burden of Streptococcus pneumoniae disease in
HIV-infected persons. We describe the burden and risk factors for pneumococcal disease in the modern era of HIV
care and evaluate the use of a 23-valent pneumococcal polysaccharide vaccine (PPV-23).
Methods: The incidence of invasive pneumococcal disease (IPD) between January 1
st, 2000 and January 1
st, 2010
in a regional HIV population in Southern Alberta, Canada was determined by linking comprehensive laboratory and
hospital surveillance data. Clinical and epidemiologic data including risk factors for S. pneumoniae, history of
pneumococcal immunization, serotypes of infections, and length of any hospitalizations for pneumococcal disease
were evaluated with multivariate analysis. CD4 count and viral load at immunization were evaluated with a nested
case-control analysis.
Results: In 1946 HIV-patients with 11,099 person-years of follow up, there were 68 distinct episodes of
pneumococcal disease occurring in 50 patients. Increased risk was seen if female, age >60, Aboriginal ethnicity,
lower education, injection drug use, smoking, nadir CD4 <200/μL, chronic obstructive pulmonary disease, and
hepatitis C. Overall, the incidence of IPD was 342/100,000 person-years and was reduced to 187/100,000 within
three years of PPV-23 immunization (P < 0.01). Although 78% of patients received PPV-23, 74% of IPD episodes
were caused by PPV-23 serotypes. In a case-control analysis, HIV viral load at immunization was significantly
predictive of PPV-23 failure, while CD4 count was not. 80% of IPD cases required hospitalization: median length of
stay was 7 days (range: 1-71); four patients died.
Conclusions: Despite universal access to intensive measures to prevent pneumococcal disease including the
widespread use of HAART and PPV-23 immunization, the incidence of IPD remains high in HIV patients with its
associated morbidity and mortality.
Background
Streptococcus pneumoniae causes significant morbidity
and mortality in the presence of HIV infection, where it
is the most common cause of bacterial pneumonia [1].
Many of the behavioral and demographic factors that
increase the risk for invasive pneumococcal disease
(IPD) in the general population such as smoking, injec-
tion drug use (IDU), alcohol abuse, race, lung disease,
and close contact with children are more common in
HIV-infected populations [2]. However, the precise role
and importance of these factors in the context of an
HIV infected population has not been explored [2].
The incidence of IPD in HIV patients prior to the
introduction of highly active antiretroviral therapy
(HAART) was well described [3-6]. Shortly after the
introduction of HAART in 1996 some, but not all HIV
care centres, have reported a decline in the incidence of
IPD in their patients [7-9]. During the early HAART era
(between 1996 and 2003), incidence estimates of IPD in
developed countries range from 379 to 820/100,000 per-
son-years [6,9]; still occurring at a frequency of up to
35-100 times more than the HIV seronegative
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and of newer regimens on the incidence of IPD is not
well established. In the general population, a decline in
the burden of pneumococcal disease in adults has been
reported after the introduction of the 7-valent pneumo-
coccal conjugate vaccine (PCV7) for childhood immuni-
zations due to “herd immunity” [10,11]. This may have
also had a secondary and beneficial effect on incidence
of pneumococcal infection in HIV patients [12].
As little is reported on the current incidence and mor-
bidity of IPD in HIV-infected populations, we sought to
examine the burden of pneumococcal disease in the
new era of widespread use of HAART and active immu-
nization programs in both HIV patients and the wider
community.
Methods
The Southern Alberta Clinic (SAC) and Calgary Labora-
tory Services (CLS) are the exclusive providers of HIV
care and all routine laboratory services respectively in
Calgary, Canada. Patients accessing care at SAC sign a
voluntary informed consent form allowing administra-
tive data to be used in research projects as approved by
the University of Calgary Ethics Committee. Hospitaliza-
tion data including discharge diagnoses from all city
hospitals on SAC patients are collected and available
within the SAC database [13]. Hospitalizations were
included if a primary cause for admission was pneumo-
coccal disease. Length of stay was evaluated using pre-
viously described methodology [13].
All HIV patients with cultures positive for S. pneumo-
niae growth between January 1
st, 2000 and January 1
st,
2010 were identified by reviewing the clinical database,
which contains all of the microbiology results, provided
to us by CLS. The results were reconciled for both com-
pleteness and for verification with hospitalization data.
IPD was diagnosed when the culture was isolated from a
normally sterile site such as blood, peritoneum, pleura, or
cerebrospinal fluid (CSF); all such isolates were sero-
typed. Pneumococcal pneumonia was defined as isolation
from a sputum sample or via bronchoalveolar lavage
(BAL); most BAL isolates were also serotyped. Sputum
and BAL samples were obtained because of strong clini-
cal suspicion for lower respiratory tract infection, gener-
ally associated with radiologic evidence and severe illness.
The follow-up period was measured from the initial
HIV-care visit until the patient moved, died, was discon-
nected from care, or until January 1
st, 2010; this was
used to calculate incidence rates [14]. If a patient pre-
sented with recurrent pneumococcal disease multiple
times in one year, only the first instance was counted in
an effort to reduce data distortion by a few patients
with multiple recurrent cases. Clinical information
obtained through routine care was evaluated with
multivariate binary logistic regression. These risk factors
included gender, age group (≤30, 31-45, 46-60, or ≥61),
race (white, Aboriginal, black, or other), education (<
high school or ≥ high school), a smoking history (if >1
month), alcohol abuse (>9 drinks/week for females, >14
drinks/week for males), IDU (at any time), nadir CD4
cell count (≤200, 201-500, or >500/μL), co-trimoxazole
use, frequency of pneumococcal immunization (never, <
every 5 years, or ≥ every 5 years), history of active tuber-
culosis (any clinical event), history of a common HIV-
associated pulmonary disease (mycobacterium avium
complex or Pneumocystis Jiroveci pneumonia), asthma,
chronic obstructive pulmonary disease (COPD), or hepa-
titis C. All risk factors were adjusted for gender, age, a
smoking history, IDU, and nadir CD4 cell count. These
confounders were selected a priori based on expert opi-
nion and previous studies [2,8,9]. Pearson’s c
2 and
adjusted odds ratios with 95% confidence intervals (or P
< 0.05) were used to evaluate significance. All demo-
graphic information was self-defined.
The effect of immunization with a 23-valent pneumo-
coccal polysaccharide vaccine (PPV-23, Merck Frosst,
Kirkland, Quebec, Canada) on the incidence of IPD was
analyzed by comparing number of episodes during the
total patient-time without immunization with the time
post-immunization. The post immunization time was
then sub-divided into categories: within three years of
immunization, three to five years post-immunization,
and greater than five years post-immunization. Any epi-
sodes of IPD within 30 days of immunization were to be
excluded. Patients were immunized with two doses of
PPV-23 five years apart and with a repeat dose every
five years based on clinical discretion.
A nested case-control study was performed in patients
who received PPV-23 comparing patients who developed
IPD versus those who did not in a 1:3 ratio to evaluate
the interaction of HIV-specific markers, while control-
ling for other known risks. Each patient diagnosed with
IPD was randomly matched with three patients with the
same age group, gender, smoking history, and history of
IDU who also received PPV-23 but had not been diag-
nosed with IPD. Differences in HIV viral load and CD4
cell count at the time of immunization were evaluated
with Levene’s test for non-significance, followed by a 2-
tailed t-test of means. An additional multivariate analy-
sis included both CD4 count and viral load. Differences
in nadir CD4 count, a history of COPD, asthma, and
hepatitis C were also evaluated.
Statistical analyses were conducted with SPSS, version
15.0 for Windows (SPSS Inc., Chicago, Illinois).
Results
Our data search revealed ten cases of pneumococcal dis-
ease (six IPD and four proven pneumococcal
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time of their presentation. These cases were excluded
from further analysis, as they had not yet engaged in
HIV care.
In a total of 1946 HIV patients in Southern Alberta
over a ten-year period, there were 68 episodes of pneu-
mococcal disease occurring in 50 patients. These
included nine recurrent but distinct episodes of IPD (in
six patients) that occurred within one year of a previous
episode of IPD. There were 46 episodes of IPD; of these,
7 had positive sputum or BAL samples. There were 22
episodes of illness where S. pneumoniae was isolated
from sputum or BAL only. Four patients died as a result
of complications from IPD giving a case-fatality rate of
8.0% (95% CI: 2.4%-22%).
Incidence
There was a total of 11,099 person-years of clinic fol-
low-up (median days/person: 2010, range: 3-3653); giv-
ing crude incidence rates of 342 and 613 cases per
100,000 person-years for IPD and all confirmed pneu-
mococcal disease, respectively. A spike in 2007 was
coincident with an outbreak of serotype 5 infections in
the community (Figure 1) [10].
Risks factors
Female gender (P < 0.01), age >60 (P < 0.0001), Aborigi-
nal ethnicity (P < 0.05), lower education (P < 0.05), IDU
(P < 0.01), smoking (P < 0.0001), nadir CD4<200/μL( P
< 0.10), COPD (P < 0.05), and hepatitis C (P < 0.0001)
were all independently associated with developing any
pneumococcal disease in the multivariate analysis (table
1). Risk factors were similar for pneumococcal pneumo-
nia and IPD. In ten patients with a splenectomy, there
were no cases of IPD and one episode of non-bactere-
mic pneumococcal pneumonia.
Microbiology
In 46 cases of IPD, S. pneumoniae was isolated exclu-
sively in the blood in 43, once from ascitic fluid, once
from both blood and ascitic fluid, and once from both
blood and pleural fluid. S. pneumoniae was not isolated
from the CSF or other sterile sites. Serotypes identified
in sterile site cultures and BAL samples are shown in
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Figure 1 Number and type of pneumococcal infections per year. Pneumococcal disease in Southern Alberta HIV patients over 10 years;
there is no evidence of a decreasing trend. The peak in 2007 overlaps with a serotype 5 outbreak among Calgary’s homeless community [10];
number of active patients at the midpoint of each year.
Siemieniuk et al. BMC Infectious Diseases 2011, 11:314
http://www.biomedcentral.com/1471-2334/11/314
Page 3 of 8Figure 2. A specific S. pneumoniae serotype was identi-
fied in 55 of 60 total isolates (92%): 45 were from sterile
sites, while 10 were isolated via BAL, and 6 were identi-
fied in a sterile site and via BAL on the same patient
during the same incident. In one patient, two different
serotypes (11A & 15B) were isolated from blood samples
taken one day apart. Therefore, a total of 50 samples
were included in the final analysis. PPV-23 covered 74%
of all samples, including 19/29 (66%) of serotypes iso-
lated from people who have previously been immunized
and 18/21 (86%) of serotypes from people who had not
been immunized (P = 0.10).
We also evaluated serotype trends over the course of
the study period in the context of routine childhood
immunization with PCV7, which was introduced in
2002 [15]. Before the introduction of PCV7 (January 1
st,
2000 to December 31
st, 2001), 1 of 4 incidents was due
to a serotype covered by PCV7. In the immediate period
the after the introduction of PCV7 (January 1
st, 2002 to
December 31
st, 2004), 2 of 9 (22%) were PCV7 sero-
types. After PCV7 was well established in our commu-
nity (January 1
st,2 0 0 5t oJ a n u a r y1
st,2 0 1 0 ) ,2o f3 7
(5.4%) isolates were PCV7 serotypes; which represents a
non-significant decrease compared to the period prior
to 2005 (P = 0.10).
Immunization
429 patients never received PPV-23 either because they
declined immunization, were missed, or had CD4 counts
below the recommended threshold. 1517 (78%) patients
received PPV-23. Of these, 523 (34%) patients received
two or more doses of PPV-23. Of a total 11,099 person-
years of exposure for clinic patients, 2084 were prior to
any PPV-23 immunization, and 9015 were post-immuni-
zation. 6578 person-years of follow-up were within 5
years after PPV-23 administration (4822 within 3 years)
and 2437 follow up years were more than 5 years post-
PPV-23 (Figure 3). There were no cases of pneumococ-
cal disease within one month post-immunization. The
incidence of IPD was significantly lower post-immuniza-
tion for serotypes covered by PPV-23 (189 vs. 720 per
100,000 person-years, P < 0.0001) and for all serotypes
(244 vs. 768 per 100,000 person-years, P < 0.001).
In a 1:3 case-control analysis of immunized patients,
t h ec a s eg r o u p( d i a g n o s e dw i t ha tl e a s to n ei n c i d e n to f
IPD, n = 19) had a significantly higher average log of
viral load at the time of PPV-23 administration (P <
0.05). The mean (SD) of the log of viral load of cases
and controls was 3.8 (1.2) and 3.1 (1.2), respectively.
The viral load remained a significant predictor (P <
0.05) of IPD post-immunization when CD4 count at
immunization was controlled for in multivariate analysis.
CD4 counts were similar in the case group (mean: 430/
μL SD: 190) and control groups (mean: 472/μL SD: 230,
P = 0.44) at the time of immunization. No significant
differences in nadir CD4, history of COPD, asthma, or
hepatitis C were identified between groups (data not
shown).
Hospitalization
Hospitalization data were available to mid-2009 [13]. 45
of 64 (70%) cases of confirmed pneumococcal disease
required in-patient care at the time of diagnosis, includ-
ing 35 of 44 (80%) cases of IPD. The median length of
stay when a primary diagnosis was pneumococcal dis-
ease was 7 days (range: 1-71 days).
Discussion
The landscape of HIV care has changed dramatically
over the last decade. The availability of newer and bet-
ter-tolerated ART, the shift towards earlier therapy, and
guidelines promoting more aggressive immunization in
HIV infection have all contributed to improving morbid-
ity and mortality. The effect of these improvements on
IPD has not yet been scrutinized. Despite these advances
in care, the incidence of IPD among our cohort has
remained high.
In the United States, black race has been consistently
correlated with increased risk of pneumococcal disease
[9]. We identified that the highest rates of pneumococ-
cal disease occurred in the Aboriginal population, but
not in the black population, which locally consists
mainly of recent migrants to Canada from Sub-Saharan
Africa [16]. We are the first to report on the high inci-
dence of pneumococcal disease in HIV-positive Aborigi-
nal patients. Risk factors for pneumococcal disease
identified are grossly otherwise consistent with previous
studies [2,8,9]. While genetic factors may be important
in this population in determining pneumococcal sus-
ceptibility or vaccine response, such differences have not
been shown to be important in other ethnicities [17].
We suspect social and economic factors are more
important and the pneumococcal epidemic in our popu-
lation in 2007 may have particularly affected the disease
incidence in this population.
Current WHO guidelines recommend immunization
with PPV-23 for HIV patients in clinical stage 1 [18],
while the CDC recommends immunization in those
with a CD4 cell count greater than 200/μL [19]. Robust
s t u d i e so fP P V - 2 3i nH I V - i n f e c t e dp e r s o n sa r el a c k i n g
[2] and there has only been one randomized control
trial of the PPV-23 effectiveness in HIV-infected
patients, which showed harmful outcomes in a Ugandan
population [20]. This study, however, did not report the
use of ART and was undertaken at a time when potent
HAART was unavailable to this population, making the
trial results difficult to evaluate in the context of current
care in the developed world.
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Risk Factor IPD Pneumococcal Pneumonia All Pneumococcal Disease
n n (%) AOR (95% CI) n (%) AOR (95% CI) n (%) AOR (95% CI)
Gender
Female 418 10 (2.4) 2.2 (1.0-4.9) 10 (2.4) 3.4 (1.5-7.9) 16 (3.8) 2.6 (1.3-4.9)
Male 1528 22 (1.4) 1 18 (1.2) 1 34 (2.2) 1
Age
≥61 58 3 (5.2) 9.7 (1.7-53.8) 4 (6.9) 45.4 (4.6-445.0) 6 (10.3) 22.5 (5.0-100.7)
46-60 476 11 (2.3) 2.5 (0.7-9.5) 4 (0.8) 2.9 (0.3-26.7) 12 (2.5) 2.8 (0.8-10.5)
31-45 1070 15 (1.4) 1.5 (0.4-5.5) 19 (1.8) 6.4 (0.8-49.2) 29 (2.7) 3.2 (0.9-10.8)
≤30 342 3 (0.9) 1 1 (0.3) 1 3 (0.9) 1
Race
Aboriginal 233 13 (5.6) 3.0 (1.3-6.8) 7 (3.0) 1.5 (0.6-3.8) 16 (0.7) 2.1 (1.1-4.3)
Black 329 1 (0.3) 0.5 (0.1-3.9) 1 (0.3) 0.4 (0.0-3.7) 2 (0.6) 0.5 (0.1-2.3)
White 1225 18 (1.5) 1 19 (1.6) 1 31 (2.5) 1
Other 124 0 – 1 (0.8) – 1 (0.8) –
Unknown 35 0 – 0 – 0 –
Education
<High School 437 15 (3.4) 1.8 (0.8-3.9) 15 (3.4) 2.2 (1.0-4.8) 24 (5.5) 1.9 (1.0-3.5)
≥High School 1155 15 (1.3) 1 13 (1.1) 1 24 (2.1) 1
Unknown 354 2 (0.6) – 0 – 2 (0.6) –
IDU
Yes 231 13 (5.6) 3.3 (1.5-7.2) 7 (3.0) 1.4 (0.5-3.4) 17 (7.4) 2.5 (1.3-4.8)
No 1715 19 (1.1) 1 21 (1.2) 1 33 (1.9) 1
Smoker*
Yes 1042 28 (2.7) 4.9 (1.6-14.7) 26 (2.4) 13.8 (3.1-60.9) 44 (4.2) 6.2 (2.5-15.3)
No 902 4 (0.4) 1 2 (0.2) 1 6 (0.7) 1
Alcohol abuse†
Yes 266 7 (2.6) 1.4 (0.6-3.5) 7 (2.6) 1.6 (0.6-4.0) 11 (4.1) 1.4 (0.7-2.9)
No 1680 25 (1.5) 1 21 (1.3) 1 39 (2.3)
Nadir CD4/μL
≤200 875 27 (3.1) 5.1 (0.7-38.3) 22 (2.5) 1.5 (0.4-5.3) 41 (4.7) 2.8 (0.8-9.2)
201-500 836 4 (0.5) 1.0 (0.1-8.6) 3 (0.4) 0.2 (0.0-1.2) 6 (0.7) 0.5 (0.1-2.0)
>500 179 1 (0.6) 1 3 (1.7) 1 3 (1.7) 1
Not Available 56 0 – 0 – 0 –
Any co-trimoxazole use
Yes 656 21 (3.2) 1.4 (0.6-3.4) 18 (2.7) 1.8 (0.7-4.8) 33 (5.0) 1.7 (0.8-3.5)
No 1290 11 (0.9) 1 10 (0.8) 1 17 (1.3) 1
PPV-23 frequency
Never 429 9 (2.1) 1.7 (0.7-4.5) 2 (0.5) 0.3 (0.1-1.4) 10 (2.3) 1.0 (0.5-2.4)
< once per 5 years 472 12 (2.5) 2.3 (1.0-5.4) 12 (2.5) 1.8 (0.8-4.1) 20 (4.2) 2.1 (1.1-4.1)
≥ once per 5 years 1045 11 (1.1) 1 14 (1.3) 1 20 (1.9) 1
History of pulmonary MAC or PCP
Yes 243 8 (3.3) 1.5 (0.6-3.6) 6 (2.5) 1.2 (0.5-3.2) 11 (4.5) 1.2 (0.6-2.6)
No 1703 24 (1.4) 1 22 (1.3) 1 39 (2.3) 1
History of asthma
Yes 178 5 (2.8) 1.4 (0.5-4.0) 5 (2.8) 1.7 (0.6-4.8) 8 (4.5) 1.5 (0.7-3.5)
No 1768 27 (1.5) 1 23 (1.3) 1 42 (2.4) 1
History of COPD
Yes 60 4 (6.7) 1.3 (0.4-4.3) 6 (10.0) 3.8 (1.3-11.0) 9 (15.0) 2.7 (1.1-6.4)
No 1886 28 (1.5) 1 22 (1.2) 1 41 (2.2) 1
History of active TB
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lower in those who had been immunized. By using the
incidence of clinical disease, we found that the viral load
at the time of PPV-23 immunization was the most sig-
nificant predictor of PPV-23 failure to provide protec-
tion. This has been shown with other vaccines in HIV
populations, in conjunction with CD4 cell count [18,21].
The effect of CD4 is more difficult to evaluate due to
confounding use of antibiotic prophylaxis (usually
including co-trimoxazole) against Pneumocystis Jirovecii
pneumonia in patients with low CD4 counts.
Despite immunization, many of our patients developed
IPD from serotypes included in PPV-23. This subopti-
mal protection in HIV patients has been previously
Table 1 Risk factors for pneumococcal disease in HIV patients (Continued)
Yes 74 2 (2.7) 1.5 (0.3-6.8) 1 (1.4) 0.9 (0.1-7.0) 3 (4.1) 1.5 (0.4-5.3)
No 1872 30 (1.6) 1 27 (1.4) 1 47 (2.5) 1
Hepatitis C
Infected 448 22 (4.9) 5.0 (2.0-12.1) 16 (3.6) 3.1 (1.3-7.7) 31 (6.9) 3.9 (1.9-7.9)
Not Infected 1498 10 (0.7) 1 12 (0.8) 1 19 (1.3) 1
* Self-reported smoking for greater than one month
† >9 drinks/week for females, >14 drinks/week for males
AOR, adjusted odds ratio; CI, Confidence Interval; IDU, injection drug use; PPV-23, pneumococcal polysaccharide vaccine; MAC, Mycobacterium avium complex;
PCP, Pneumocystis Jirovecii pneumonia; COPD, chronic obstructive pulmonary disease; TB, tuberculosis
Variables are adjusted with logistic regression for gender, age group (≤30, 31-45, 46-60, or ≥61), a smoking history (if >1 month), IDU, and nadir CD4 cell count
(≤200, 201-500, or >500/μL)
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Figure 2 S. pneumoniae serotypes isolated over 10 years (n = 50). Isolated incidents of S. pneumoniae serotypes from 2000-2009 are
described and arranged by coverage of three pneumococcal vaccinations. 40 were isolated from a sterile site only, 4 from bronchoalveolar
lavage (BAL) only, and 6 from both a sterile site and BAL. Lines indicate serotypes included in the 7-valent pneumococcal conjugate vaccine
(PCV7; n = 5), 13-valent pneumococcal conjugate vaccine (PCV13; n = 23), and the 23-valent pneumococcal polysaccharide vaccine (PPV-23; n =
37). *Serotype 6A is not included in PPV-23.
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Page 6 of 8recognized and led to a study investigating effectiveness
of PCV7 in HIV-infected Malawian adults [2,22]. Cau-
tion however should be used in applying these results to
a developed country with high rates of combination
ART usage and childhood pneumococcal immunization
programs. Furthermore, the placebo group had higher
baseline viral loads, rates of tuberculosis and recurrent
pneumonia, thus making the results difficult to interpret
or extrapolate to developed world. We found that PCV7
would have covered only 10% of serotyped infections
seen in our population over the last decade. A serotype
shift after the implementation of a childhood immuniza-
tion program is a plausible explanation for this low inci-
dence as this has been described in HIV patients
elsewhere, as well as the Calgary-area population
[10,12]. Our results suggest that in adult HIV popula-
tions, there may be a trend away from serotypes
included in the routine childhood vaccinations. Further
shifts may occur after PCV13 was introduced into rou-
tine care in our region in 2010. Many of the serotypes
observed in our study are included in PCV13, suggesting
that a secondary benefit from reduction in pneumococ-
cal disease among HIV-positive adults is possible.
Hospitalization is associated with a higher degree of
severity and increased costs of care: proven pneumococcal
disease usually required in-patient care. There is a high dis-
ease burden associated with pneumococcal disease in HIV-
positive patients, causing long hospitalizations with high
rates of morbidity and mortality despite widespread immu-
nization with PPV-23, HAART, and free access to care.
This study has limitations as it was confined to a geogra-
phically defined population in Southern Alberta, Canada.
Therefore, risk factors for IPD, circulating pneumococcal
serotypes and their resistance patterns, and both clinic and
community immunization practices as well as the general
health of our HIV-infected population may differ from
other populations or areas, however, risk factors were
similar to other reports and geographically-defined popu-
lations also provide the most robust opportunity for
understanding disease burden. We did not measure anti-
body levels to confirm response to PPV-23; however,
infection rates are likely of greater clinical value.
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Figure 3 Incidence of IPD with immunization. Crude incidences with 95% Poisson confidence intervals are shown for PPV-23 serotypes. The
incidence of IPD within three years of immunization was significantly lower than the incidence before immunization (P < 0.001). A composite
incidence >3 years post-immunization incidence (not shown; mean: 262, 95% CI: 131-469) was also significantly lower than incidence before
immunization (P < 0.01).
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pletely control for all social confounders associated with
receiving the vaccine. Nevertheless, the time-since immu-
nization approach, as well serotype analyses help control
for these confounders.
Conclusions
The burden of pneumococcal disease within HIV-
infected patients remains high in the current era of HIV
care, even in a population with universal access to both
HAART and pneumococcal immunization. The ongoing
burden of serious pneumococcal disease within HIV-
infected persons reinforces the need for newer interven-
tions and approaches such as reducing modifiable risk
factors and enhanced multivalent conjugate vaccines to
reduce pneumococcal-caused morbidity and mortality.
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